AbbVie Inc. has recently announced a significant agreement to acquire the lead investigational candidate for moderate-to-severe major depressive disorder (MDD) from Gilgamesh Pharmaceuticals Inc. This deal, valued at up to $1.2 billion, includes upfront payment and development milestones for the bretisilocin program. As part of this transaction, Gilgamesh will establish a new entity, Gilgamesh Pharma Inc., to oversee its employees and other ongoing programs, such as blixeprodil (GM-1020) and a collaboration with AbbVie. This acquisition further strengthens the partnership established in 2024 between the two companies to advance next-generation psychiatric therapies.
Psychedelic compounds, particularly 5-HT2A receptor agonists, have emerged as promising treatments for mental health disorders like MDD due to their rapid, robust, and enduring antidepressant effects. However, current agents in this class often come with the drawback of prolonged psychoactive experiences. Bretisilocin, a novel 5-HT2A receptor agonist and 5-HT releaser, represents a next-generation psychedelic compound specifically designed to tackle the developmental challenges associated with existing agents. Notably, bretisilocin has demonstrated a shorter duration of psychoactive effects while maintaining prolonged therapeutic benefits.
Recent topline results from a Phase 2a study evaluating bretisilocin in MDD have shown promising outcomes. The study revealed a clinically significant and statistically considerable reduction in the severity of depressive symptoms compared to a low-dose active comparator, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. Notably, on Day 14, a single dose of bretisilocin (10mg) led to an antidepressant effect with a substantial change in MADRS total score from baseline, outperforming the low-dose (1mg) active comparator. Importantly, bretisilocin demonstrated good tolerability with no reported serious adverse events.
The strategic acquisition of Gilgamesh Pharmaceuticals’ bretisilocin program by AbbVie signifies a significant step towards advancing innovative therapies for MDD. By investing in next-generation psychedelic compounds with improved efficacy and tolerability profiles, AbbVie aims to address the unmet needs in mental health treatment. The collaboration between AbbVie and Gilgamesh Pharma Inc. holds the potential to bring forth novel treatment options for individuals suffering from MDD and other psychiatric disorders, ultimately enhancing patient outcomes and quality of life.
In conclusion, AbbVie’s $1.2 billion agreement for the next-generation psychedelic depression treatment from Gilgamesh Pharmaceuticals marks a pivotal moment in the development of innovative therapies for mental health disorders. The advancements in psychedelic compounds, particularly bretisilocin, offer promising prospects for more effective and well-tolerated treatments for conditions like MDD. This strategic move underscores AbbVie’s commitment to pushing the boundaries of therapeutic innovation and addressing the evolving needs of patients with psychiatric disorders.
- AbbVie’s acquisition of Gilgamesh Pharmaceuticals’ bretisilocin program signifies a significant investment in next-generation psychedelic compounds for treating MDD.
- Bretisilocin has shown promising results in reducing depressive symptoms with a shorter duration of psychoactive effects compared to existing agents.
- The collaboration between AbbVie and Gilgamesh Pharma Inc. holds the potential to introduce novel treatment options for individuals with MDD and other psychiatric disorders.
- This strategic move highlights AbbVie’s dedication to advancing innovative therapies and addressing the unmet needs in mental health treatment.
Read more on benzinga.com